Medicare's Transforming Episode Accountability Model is projected to save $46.6 million by 2030, with safety-net hospitals ...
Conclusions: Cancer costs for employers are not uniformly increasing, but instead, shifting based on market competition and therapeutic innovation. Where costs are rising, they are driven by novel ...
Employer-mandated high-deductible health plan enrollment was not associated with reduced use of oral targeted anticancer ...
CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to ...
MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, ...
Gray market peptides cause vague symptoms patients may not disclose or link, so serious harms can go unnoticed until late, ...
Goad, PharmD, MPH, of Chapman University explains why pharmacists are trusted, accessible sources for COVID-19 vaccine ...
Telitacicept has the first regulatory approval for Sjögren disease (China), while global phase 3 programs aim to support ...
Weekly survodutide 3.6 mg/6.0 mg achieved up to 13.1% mean weight loss at week 76 versus 3.1% with placebo, meeting ...
Rotterdam-based diagnosis (2 of oligo/anovulation, hyperandrogenism, polycystic ovarian morphology) persists, but ...
Lung cancer screening eligibility increased markedly from 2018–2023 under USPSTF criteria, reflecting aging and substantial ...
FDA authorized frontline pirtobrutinib for previously untreated CLL/SLL without known 17p deletion, expanding use beyond its established relapsed/refractory setting after covalent BTK inhibition.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results